Systemic therapy for RCC, including inhibition of the VEGF signaling pathway using VEGFR tyrosine kinase inhibitors (VEGFR TKIs) and anti-VEGF-Aantibodies, inhibition of the mTOR signaling pathway, and immune checkpoint inhibitors, have shown remarkable efficacy in patients with metastatic RCC [46,47,48]. The gene discussed is KDR; the disease is renal cell carcinoma.